Multiple Interleukins

PsiThera's Multiple Interleukins program is an exploratory-stage research initiative focused on developing oral small-molecule therapeutics that modulate multiple interleukin cytokine targets. Utilizing an 'Antibody-in-a-Pill' strategy, the program aims to provide oral alternatives to injectable biologics that currently dominate the treatment landscape for inflammatory and immunological diseases. The development process leverages predictive computational R&D models, combining physics, AI, and structural data to target cytokine systems that have traditionally been difficult to address with small molecules. As of late 2025, the specific interleukin targets and lead candidates within this program remain undisclosed.

Other names

Multiple Interleukins program